The total number of BC patients in our cohort (sub-cohort 1) included 53,777 Luminal A patients (70.5%), 8,790 Luminal B patients (11.5%), 3,699 HER2 patients (4.8%), and 10,044 TNBC patients (13.2%) (Table 1). This evidence concerns the gene ERBB2 and breast cancer.